Ella Hohmann, MS

Endometriosis increases ovarian cancer risk, but endometriosis-associated ovarian cancer shows favorable tumor characteristics and better survival.

The FDA announcement seeks nominees from the public for drug repurposing, leveraging AI signals to expand treatment options for rare diseases and other unmet needs.

Deep learning model beats breast density for 5-year breast cancer risk, informing supplemental screening decisions and personalized care.

Fears that the telemedicine boom would send health care costs soaring haven’t been borne out, a major new study finds, and the timing couldn’t be more critical for federal policy makers.

New review maps how endometriosis hijacks glucose, lipid, and amino acid metabolism to fuel lesion survival, immune evasion, and infertility.

Health-system specialty pharmacies leverage EHR insights to enhance real-world evidence, improve access, and streamline prior authorizations.

New soft tissue sarcoma radiotherapy guidelines favor preoperative radiotherapy, refine dosing and targeting, and preview the role of immunotherapy and hypofractionation.

Amid breast cancer surging in women under 50, new data and WISDOM trial results support individualized screening over age-based guidelines.

Fatima Cody Stanford, MD, MPH, MPA, exposes obesity health disparities, GLP-1 access hurdles, payer policy fixes, and how stigma in care blocks equitable treatment.

This FDA approval brings the first heterobifunctional protein degrader for HER2-negative, ESR1-mutant breast cancer, improving PFS after endocrine therapy.

Fatima Cody Stanford, MD, MPH, MPA, breaks down the brain mechanisms behind obesity and how to empower patients and improve clinical outcomes.

Rani Bansal, MD, discusses breast cancer subtypes, racial disparities in triple-negative disease, self-advocacy for young patients, and diversity in clinical trials.

The therapy receives FDA approval for Alzheimer disease agitation, backed by phase 3 data showing significant symptom reduction and delayed relapse vs placebo.

Experts at AXS26 laid out why advanced therapies are underutilized and what payers, providers, and manufacturers must do together to change that.

At NAACOS 2026, value-based care leaders make the case for treating payers as partners and explain what providers must see in return.

Rani Bansal, MD, explores what's driving the surge in breast cancer in young women and why earlier, risk-based screening matters.

Discussion covered lung cancer biomarker testing, care in hematologic malignancies, health equity in cancer screening, and medically integrated pharmacy dispensing

A new AHIP report outlines evidence-based strategies to cut chronic disease prevalence by 10% by 2035.

Results of 2 programs show what it takes to move social determinants of health from research into clinical practice—and what’s still missing.

LaShawn McIver, MD, MPH, discusses a new report from a task force aiming to cut chronic disease prevalence 10% by 2035 through prevention and coordinated care.

Alyson Moadel-Robblee, PhD, outlines how the BOLD Program proactively supports cancer caregivers through community-based care.

Alyson Moadel-Robblee, PhD, provides a closer look at how families, especially children, experience a breast cancer diagnosis and why transparency and inclusion are key to healthy coping.

Oral semaglutide hasn't shifted prescribing as expected. Shawn Davis, MD, discusses what access and policy changes are needed to close the coverage gap.

Tim Church, MD, PhD, MPH, explains that access to care—not willpower—is the central barrier to GLP-1 use, and says employer coverage decisions are finally catching up.

Five vaccines in development for HIV, tuberculosis, cancer, influenza, and coronaviruses could transform global health.

Family caregivers absorb enormous burden after a breast cancer diagnosis, so routine caregiver support is vital.

A 2026 survey finds 2 in 3 employed adults would be more likely to use GLP-1 weight-loss drugs if employer coverage or behavioral support programs were available.

Douglas Marks, MD, discusses how diet, exercise, and alcohol reduction can meaningfully lower breast cancer risk

With obesity costing $1.4 trillion annually, Shawn Davis, MD, argues the return on treatment investment is clear if we build systems to measure it.

Shawn Davis, MD, explains why shifting from BMI to adiposity-based care could transform how health systems allocate resources and reduce obesity-driven hospital costs.